Rep. Jonathan L. Jackson Sells Off Shares of Doximity, Inc. (NASDAQ:DOCS)

Representative Jonathan L. Jackson (D-Illinois) recently sold shares of Doximity, Inc. (NASDAQ:DOCS). In a filing disclosed on December 05th, the Representative disclosed that they had sold between $15,001 and $50,000 in Doximity stock on November 6th. The trade occurred in the Representative’s “MORGAN STANLEY TRUST ACCOUNT” account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 11/11/2025.
• Purchased $1,001 – $15,000 in shares of State Street (NYSE:STT) on 11/11/2025.
• Sold $1,001 – $15,000 in shares of T-Mobile US (NASDAQ:TMUS) on 11/11/2025.
• Purchased $15,001 – $50,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 11/6/2025.
• Purchased $1,001 – $15,000 in shares of Shopify (NASDAQ:SHOP) on 10/8/2025.
• Sold $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 10/8/2025.
• Purchased $15,001 – $50,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 10/8/2025.
• Purchased $15,001 – $50,000 in shares of Shopify (NASDAQ:SHOP) on 10/6/2025.

Doximity Trading Down 0.2%

Shares of NASDAQ:DOCS traded down $0.10 during trading on Tuesday, reaching $45.58. 1,687,708 shares of the company traded hands, compared to its average volume of 2,127,997. Doximity, Inc. has a 52-week low of $44.98 and a 52-week high of $85.21. The business’s fifty day moving average is $60.21 and its 200-day moving average is $61.68. The firm has a market capitalization of $8.58 billion, a price-to-earnings ratio of 45.60, a P/E/G ratio of 4.10 and a beta of 1.38.

Doximity (NASDAQ:DOCS) last posted its earnings results on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.07. Doximity had a return on equity of 21.75% and a net margin of 36.60%.The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.30 EPS. On average, sell-side analysts predict that Doximity, Inc. will post 0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Doximity

In other news, Director Regina M. Benjamin sold 5,000 shares of Doximity stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $70.84, for a total transaction of $354,200.00. Following the sale, the director owned 19,839 shares in the company, valued at $1,405,394.76. This trade represents a 20.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kira Scherer Wampler sold 2,000 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $66.44, for a total transaction of $132,880.00. Following the transaction, the director owned 19,839 shares of the company’s stock, valued at approximately $1,318,103.16. This represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 32,000 shares of company stock valued at $2,339,580 in the last three months. 31.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Doximity

A number of hedge funds have recently modified their holdings of the business. Bank of Nova Scotia purchased a new position in shares of Doximity in the first quarter valued at about $651,000. Jump Financial LLC bought a new stake in Doximity during the 1st quarter valued at approximately $3,125,000. Hsbc Holdings PLC lifted its holdings in Doximity by 752.1% in the 1st quarter. Hsbc Holdings PLC now owns 141,191 shares of the company’s stock worth $8,120,000 after purchasing an additional 124,622 shares in the last quarter. Strs Ohio bought a new position in Doximity in the 1st quarter worth approximately $665,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Doximity in the 1st quarter worth approximately $801,000. Institutional investors own 87.19% of the company’s stock.

Wall Street Analysts Forecast Growth

DOCS has been the topic of several research reports. Evercore ISI dropped their price objective on shares of Doximity from $81.00 to $70.00 and set an “outperform” rating on the stock in a research note on Friday, November 7th. JPMorgan Chase & Co. reiterated an “underweight” rating and set a $62.00 price target on shares of Doximity in a report on Friday, October 10th. KeyCorp raised their price target on shares of Doximity from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Zacks Research lowered shares of Doximity from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Finally, Barclays started coverage on Doximity in a research note on Monday. They set an “overweight” rating and a $63.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $67.95.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois’ 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois’ 1st Congressional District. He declared candidacy for the 2026 election.

Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson’s career experience includes working as an investment analyst and an entrepreneur.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.